Capricor Therapeutics (CAPR) Insider Trading & Ownership $7.82 -0.14 (-1.78%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Capricor Therapeutics (NASDAQ:CAPR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$15.00MNumber OfInsiders Selling(Last 12 Months)0 Get CAPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Capricor Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CAPR Insider Buying and Selling by Quarter Capricor Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/20/2024Shinyaku Co Ltd NipponMajor ShareholderBuy2,798,507$5.36$14,999,997.52 (Data available from 1/1/2013 forward) CAPR Insider Trading Activity - Frequently Asked Questions Who is on Capricor Therapeutics' Insider Roster? The list of insiders at Capricor Therapeutics includes David B Musket, Paul Gisbert Auwaerter, Shinyaku Co Ltd Nippon, and Xavier Avat. Learn more on insiders at CAPR. What percentage of Capricor Therapeutics stock is owned by insiders? 10.50% of Capricor Therapeutics stock is owned by insiders. Learn more on CAPR's insider holdings. Which Capricor Therapeutics insiders have been buying company stock? The following insiders have purchased CAPR shares in the last 24 months: David B Musket ($22,711.56), Paul Gisbert Auwaerter ($14,200.00), and Shinyaku Co Ltd Nippon ($14,999,997.52). How much insider buying is happening at Capricor Therapeutics? Insiders have purchased a total of 2,811,500 CAPR shares in the last 24 months for a total of $15,036,909.08 bought. Capricor Therapeutics Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More Insider Trading Tools from MarketBeat Related Companies Apogee Therapeutics Insider Ownership Immunocore Insider Ownership Dyne Therapeutics Insider Ownership Cidara Therapeutics Insider Ownership Twist Bioscience Insider Ownership Travere Therapeutics Insider Ownership Biohaven Insider Ownership Aurinia Pharmaceuticals Insider Ownership Schrodinger Insider Ownership Janux Therapeutics Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried? This page (NASDAQ:CAPR) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access